See more : Superbag Company, Limited (3945.T) Income Statement Analysis – Financial Results
Complete financial analysis of Vera Therapeutics, Inc. (VERA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vera Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Winix Inc. (044340.KQ) Income Statement Analysis – Financial Results
- Avix Technologies, Inc. (AVIX) Income Statement Analysis – Financial Results
- Blivex Energy Technology Co., Ltd (300116.SZ) Income Statement Analysis – Financial Results
- Xinjiang Torch Gas Co., Ltd (603080.SS) Income Statement Analysis – Financial Results
- Mukat Pipes Limited (MUKATPIP.BO) Income Statement Analysis – Financial Results
Vera Therapeutics, Inc. (VERA)
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy. It is also developing MAU868, a monoclonal antibody for the treatment of BK viremia infections and is under Phase 2 clinical trial. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 1.86M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | -846.00K | 176.00K | 251.00K | 509.00K |
| Gross Profit | 1.86M | 846.00K | -176.00K | -251.00K | -509.00K |
| Gross Profit Ratio | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 78.23M | 68.99M | 22.48M | 45.21M | 7.29M |
| General & Administrative | 23.79M | 21.91M | 11.92M | 4.04M | 4.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 23.79M | 21.91M | 11.92M | 4.04M | 4.41M |
| Other Expenses | 0.00 | 1.85M | 1.79M | -1.08M | 0.00 |
| Operating Expenses | 102.01M | 90.90M | 34.40M | 49.25M | 11.70M |
| Cost & Expenses | 102.01M | 90.90M | 34.40M | 49.25M | 11.70M |
| Interest Income | 4.19M | 1.75M | 15.00K | 8.00K | 159.00K |
| Interest Expense | 0.00 | 992.00K | 20.00K | 166.00K | 51.00K |
| Depreciation & Amortization | 0.00 | -846.00K | 176.00K | 251.00K | 509.00K |
| EBITDA | -102.01M | -90.90M | -34.23M | -53.00M | -11.19M |
| EBITDA Ratio | -5,478.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -102.01M | -90.90M | -34.40M | -52.24M | -11.96M |
| Operating Income Ratio | -5,478.63% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.02M | 1.85M | 1.79M | -1.17M | 108.00K |
| Income Before Tax | -95.99M | -89.06M | -32.61M | -53.41M | -11.85M |
| Income Before Tax Ratio | -5,155.16% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 1.00K | 1.00K | 1.00K | 1.00K | 1.00K |
| Net Income | -95.99M | -89.06M | -32.61M | -53.41M | -11.85M |
| Net Income Ratio | -5,155.21% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.25 | -3.35 | -1.53 | -14.40 | -3.46 |
| EPS Diluted | -2.25 | -3.35 | -1.53 | -14.40 | -3.46 |
| Weighted Avg Shares Out | 42.71M | 26.57M | 21.28M | 3.71M | 3.42M |
| Weighted Avg Shares Out (Dil) | 42.71M | 26.57M | 21.28M | 3.71M | 3.42M |
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
BRISBANE, Calif., June 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will participate...
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
BRISBANE, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the U.S. Food and Drug Administration...
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
BRISBANE, Calif., May 25, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced data presentations from its Phase 2b ORIGIN...
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
BRISBANE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for...
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on May 1, 2024, the Compensation Committee of Vera's Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 15,000 shares...
Could This Stock Be the Next Biotech Buyout?
Vera Therapeutics is developing a dual-action antibody to treat kidney disorders, with successful results from the first portion of a pivotal study. Recently, Vertex Pharmaceuticals acquired Alpine Immune Sciences, another company developing an antibody that binds to the same receptors...
2 Biotech Stocks Driving the Nasdaq Today
The Nasdaq is leading the charge today, with biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) up over 2% today.
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
BRISBANE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today reported its business highlights and financial results for...
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
BRISBANE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced that the Company's management team will participate...
Insider Buying at These Biotechs Is Huge
As January wound to a close, the most notable insider purchases were in biopharma companies, particularly those with initial or secondary offerings of stock.
Source: https://incomestatements.info
Category: Stock Reports